| Date |
Subject |
Media |
| 2025-09-08 |
President Lai: Build Sovereign AI with Healthcare as a Priority Industry
|
President Lai Ching-te stated yesterday (17th) at the "Taiwan Climate and Health Alliance – Deans’ Sustainability Forum" that the government plans to invest NT$900 billion by 2030 in net-zero transformation. He also emphasized accelerating the development of sovereign AI, with healthcare identified as a priority sector, aiming to enhance the competitiveness of Taiwan’s medical industry. |
| 2025-09-08 |
BioGend Therapeutics Advances OIF Toward Phase III; RevoCart Expands Hospital Adoption
|
BioGend Therapeutics reported a significant increase in monthly procedures for its single-use autologous cartilage repair product, RevoCart, and achieved profitability in July. Looking ahead to the second half of the year, the company expects to receive the full report of its Osteogenic Inductive Factor (OIF) Phase II clinical data in August. Following this, BioGend plans to communicate with regulatory authorities regarding its Phase III clinical trial program, with an anticipated official launch in the second half of next year. Meanwhile, RevoCart is scheduled to be introduced to four major teaching hospitals in the latter half of the year. Combined with reduced impact from antibiotic production line maintenance, revenue contributions from both products are expected to achieve double-digit growth next year. |
| 2025-09-08 |
Qisda Sees Growth Across All Businesses in Q2, Healthcare and Smart Solutions Drive Steady Expansion
|
Qisda’s businesses warmed up in the second quarter compared with Q1, with both its healthcare segment and smart solutions business hitting record highs. Healthcare revenue surpassed NT$7 billion for the third consecutive quarter, while smart solutions reached NT$9.5 billion for the first time. Looking ahead to Q3, despite uncertainties from tariffs and exchange rates, healthcare and smart solutions are expected to continue stable growth. |
| 2025-09-08 |
PharmaEssentia Targets Sequential Revenue Growth with Global Expansion of Ropeg in PV; Applies for NCCN Inclusion as Recommended Therapy
|
PharmaEssentia’s novel therapy Ropeginterferon alfa-2b (Ropeg) for polycythemia vera (PV) continues to drive global sales growth, with second-quarter operating profit surging 147.57% year-over-year and earnings per share (EPS) reaching NT$2.50. At an investor conference on August 14, the management team noted that revenue is expected to keep rising quarter by quarter in the second half of the year. Ropeg is also advancing international market penetration, with regulatory approval in Mexico anticipated this year for PV, while simultaneously moving into the essential thrombocythemia (ET) market. PharmaEssentia has applied for Ropeg to be included in the U.S. National Comprehensive Cancer Network (NCCN) treatment guidelines, a move that would improve clinical accessibility, expand coverage, and potentially accelerate regulatory reviews. |
| 2025-09-08 |
HanchorBio Completes First Patient Dosing of Novel Drug HCB101 in Taiwan Head and Neck Cancer Trial, Advancing Clinical Development
|
HanchorBio, a global clinical-stage biopharmaceutical company, announced on August 13 that the first patient has been successfully dosed in an investigator-initiated trial (IIT) led by Dr. Chia-Hsun Hsieh of the Oncology Department at Linkou Chang Gung Memorial Hospital. The study is designed to evaluate HCB101 in combination with the immunotherapy pembrolizumab (Keytruda®) in patients with recurrent or metastatic head and neck cancer who are unresponsive to platinum-based chemotherapy, with the primary focus on safety and preliminary efficacy. |
| 2025-09-08 |
Foresee’s Three-Month Formulation of Camcevi Awaits U.S. FDA Approval, Targeting August 29 PDUFA Date
|
Foresee Pharmaceuticals recently announced consolidated revenue of NT$8.85 million in July, representing a month-on-month decline of 77.2% and a year-on-year decrease of 75.2%. The company attributed the drop primarily to the absence of product supply to distributors during the month, coupled with changes in distributor customer mix. Looking ahead, Foresee expects growth in the second half of the year, supported by milestone payments upon anticipated U.S. FDA approval of Camcevi’s three-month formulation on the target date of August 29. |
| 2025-09-08 |
Pilatus Biosciences and Roche Enter Clinical Collaboration on PLT012: Targeting Next-Generation Combination Therapy for Hepatocellular Carcinoma
|
Pilatus Biosciences, Inc., a biotech startup dedicated to developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced a clinical trial collaboration with Roche. Under the agreement, Roche will provide its anti–PD-L1 therapy Atezolizumab (Tecentriq®) to support Pilatus’ upcoming first-in-human Phase I trial evaluating the safety and tolerability of PLT012 in combination with Atezolizumab for patients with hepatocellular carcinoma (HCC). |
| 2025-09-08 |
Licensing Partner Expected to Announce Phase III Data for L606 in September–October; Pharmosa Biopharm Optimistic
|
Pharmosa Biopharm announced on the 13th that its licensing partner Liquidia Corporation (LQDA) plans to host an R&D Day in September–October this year to release the latest results from the open-label Phase III clinical trial of L606, an investigational therapy for pulmonary arterial hypertension (PAH, WHO Group I). The company expressed optimism about the upcoming milestone. |
| 2025-09-08 |
Heavy Ion Therapy for Pancreatic Cancer: Taipei Veterans General Hospital and NYU Langone Health Form Strategic Partnership for Patient Referral and Research
|
In a landmark Taiwan–U.S. medical collaboration, Taipei Veterans General Hospital (Taipei VGH) President Dr. Wei-Ming Chen led a delegation to visit NYU Langone Health, where both institutions signed a formal research agreement with a focus on pancreatic cancer treatment. The collaboration will prioritize heavy ion therapy, patient referral, and sharing of research outcomes. |
| 2025-09-08 |
United Orthopedic Reports Record July Revenue; H1 EPS NT$2.46, Japan and U.S. Drive Growth
|
United Orthopedic Corporation (UOC) announced its first-half financial results and July revenue performance. In the second quarter, exchange rate fluctuations and product mix impacted profitability, with both gross margin and operating margin declining by three percentage points from the prior quarter. Non-operating losses from foreign exchange further weighed on results, bringing quarterly net income after tax down to NT$46.57 million, or earnings per share (EPS) of NT$0.48. Cumulative EPS for the first half reached NT$2.46. |
